Donanemab - uh, oh





Prior suggestions that FDA Advisory Panel will convene in June to discuss donanemab submission; had a firm date been set?
June 10, 2024
Agenda, meeting format and livestream link to be posted by FDA 2 days prior.

Interesting story here that the FDA might be planning to eliminate Ad Comm voting (after the firestorm of criticism the FDA endured over their ignoring the Ad Comm vote against Aduhelm).

https://www.biospace.com/article/el...emab-adcomm-as-fda-ponders-changes-to-format/
https://www.fda.gov/advisory-commit...meeting-peripheral-and-central-nervous-system